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Abstract 
 
Artificial Intelligence (AI) in healthcare holds great potential to expand access to high-quality 
medical care, whilst reducing overall systemic costs. Despite hitting the headlines regularly and 
many publications of proofs-of-concept, certified products are failing to breakthrough to the 
clinic. AI in healthcare is a multi-party process with deep knowledge required in multiple 
individual domains. The lack of understanding of the specific challenges in the domain is, 
therefore, the major contributor to the failure to deliver on the big promises. Thus, we present a 
‘decision perspective’ framework, for the development of AI-driven biomedical products, from 
conception to market launch. Our framework highlights the risks, objectives and key results 
which are typically required to proceed through a three-phase process to the market launch of a 
validated medical AI product. We focus on issues related to Clinical validation, Regulatory 
affairs, Data strategy and Algorithmic development. The development process we propose for 
AI in healthcare software strongly diverges from modern consumer software development 
processes. We highlight the key time points to guide founders, investors and key stakeholders 
throughout their relevant part of the process. Our framework should be seen as a template for 
innovation frameworks, which can be used to coordinate team communications and 
responsibilities towards a reasonable product development roadmap, thus unlocking the 
potential of AI in medicine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Introduction 
 
Healthcare systems all over the world face tremendous challenges. The age-related illness 
burden is increasing, particularly in wealthy countries, due to ageing populations. Lifetime risk for 
cancer has reached up to 50% [1] and lifetime risk for stroke is 25% [2]. As a consequence of the 
increasing incidence of these costly diseases, along with broadening access to healthcare and 
major advances in pharmaceutical and technological disease treatment, costs are increasing 
enormously. Thus, there is an urgent need to deliver better quality healthcare while 
simultaneously lowering costs in order to keep our health care systems sustainable.  
  
Technological innovation appears to be the only mechanism which has the potential to fulfil both 
of these, seemingly contradictory, requirements. Artificial Intelligence (AI), more specifically 
machine learning(ML)-based AI, has become one of the main technologies driving the so-called 
4th industrial revolution [3]. The main ML method at the forefront are so-called deep artificial 
neural networks (ANNs). ANNs are inspired by simplified neuronal structures and consist of layers 
of artificial neurons. The strengths of the connection between neurons of different layers are 
determined in the training process and also determine the predictive capability of the model [4]. 
ANNs are general function approximators, in theory, capable of approximating any mathematical 
function of data [5]). Other non-ANN machine learning methods successfully applied in healthcare 
include decision tree algorithms [6–8], generalised linear models [9], support vector machines 
[10,11] and gaussian processes (GPs) [12,13]. Modern ML methods constitute the new state-of-
the-art in computer vision [14], natural language processing [15] and recommender systems [16–
18] facilitating technologies from smart-assistants to self-driving cars. Increasingly, they are 
applied for healthcare use cases. They have the potential to deliver personalised treatments [19–
21] and monitoring [22,23], with lower error rates [23,24], at greatly reduced costs [20,23].  
 
Many publications share the vision that AI in healthcare will achieve the above-mentioned goals 
to keep our healthcare systems sustainable, e.g. [19,20,25–27]. However, the overwhelming 
majority of reported positive studies to date are retrospective in nature and the presented 
solutions, more often than not, provide mere proofs-of-concept as evidenced by systematic 
reviews [28,29]. AI/ML-based tools which are applicable in the clinical setting - with medical device 
certification, clinical validation and routine clinical use - are still scarce. Despite a rapidly 
increasing number of scientific publications describing potential applications, products benefiting 
patients and our healthcare systems are not deployed at the rates necessary. This translational 
 gap constitutes a major public health challenge. One of the most promising technologies of recent 
years is not reaching the patients and healthcare systems in need.  
 
As the translational gap refers to a block on transforming proofs-of-concept into actual products, 
we are facing a crisis of AI in healthcare product development. Thus, in the present work, we 
outline a novel framework of AI in healthcare product development. Product development is 
defined as “the transformation of a market opportunity and a set of assumptions about product 
technology into a product available for sale” [30]. It is possible to focus on product development 
from different angles, i.e. marketing, organisational structure, engineering and operations [30]. 
However, these views are highly specialised and have a tendency to over- or under-focus on 
certain challenges. We base our framework on the model of the “decision perspective” where a 
string of decisions transform an idea into a product [30]. This model is based on the observation 
that “what is being decided” is fairly consistent over the course of all types of product development, 
whereas how decisions are implemented can vary tremendously [30]. Thus, importantly, our 
framework does not give many recommendations on how to implement the decisions that are 
suggested. We focus largely on what needs to be decided for a certain stage in development to 
proceed successfully to the next stage and what needs to be decided to keep the risks of failure 
for further stages as low as possible. 
 
The main finding that underlies the presented product development framework is that, in contrast 
to other software products, healthcare-specific differences exist in the development path of AI 
healthcare products. Product development for a typical technology start-up is long and can be 
broken down into multiple stages [31]. Typically there is an initial Formation stage, in which a 
team comes together around a potential product idea. This is followed by a Validation stage, in 
which prototypes are turned into products and an eventual business model is settled-on. And, 
finally, there is a Scaling phase, where the addition of considerable capital allows the small 
company, with a now validated product-market fit, to quickly expand to capture considerable 
market share of an existing market or to expand into a newly discovered market niche. In this 
approach, current methodologies drive entrepreneurs towards early contact with potential 
customers and early trials of incomplete versions of the final product [32]. For AI products aimed 
at healthcare, the main hidden difficulty is that in order to capture the enhanced value available 
for medical treatments evidence must first be presented that the product is safe. Additionally, to 
be incorporated into standards of care, the product must also be shown to either enhance 
treatment outcomes or decrease costs. This requires a validation pipeline tailored to regulatory 
 and clinical requirements [33], which makes data acquisition and analysis time-consuming and 
difficult. Current software product development practices are rarely a fit for both the medical 
certification as well as the clinical validation process. This - in turn - leads to a) much longer 
development cycles and b) quite different proof-points inherent in developing a product which 
must be medically certified. 
 
Thus, we argue that in order to develop an AI in healthcare product, the entire development cycle 
must be changed. We present a rethought product development cycle, primarily aimed at products 
in the clinical setting, bridging the cognitive gap between modern digital development practices 
and current biotech practices. The purpose of this map is, on one hand, to enable potential digital 
health founders in the area of AI in healthcare to have a more accurate perspective of the road 
ahead, and to allow existing digital health entrepreneurs to better allocate their resources. On the 
other hand, the framework allows scientists, regulators, investors and political actors to better 
understand the specific needs of AI in healthcare projects and enterprises.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
We have developed a framework following three consecutive phases and covering 4 domains for 
AI/ML-driven clinical product development. The 3 phases follow an entrepreneurial timeline. We 
break the process down into three distinct product development phases before a product exists 
in the market. Each of these phases is self-contained and typically can be recognised by both 
 investors and regulators as a distinct stage on the road to market. For each of the phases, our 
framework spans across four major domains which are relevant for the development of an AI/ML 
product in healthcare: clinical, regulatory, data, and model development. Finally, we present an 
overview of the most important post-market risks, delivering software updates, changes in medical 
practice and surveillance, each of which must be mitigated against once the product enters the 
market. 
 
In the following, we will give definitions of the 3 phases and 4 domains before outlining the 
framework in detail. The phases and domains are additionally depicted in Figures 1 to 4 following 
a domain perspective. 
 
Definition of the 3 phases 
 
Phase 1, called Form, involves bringing together a small team/group around a potential clinical 
need, with the purpose of providing a preliminary technical solution. This phase may take place 
within the support structures of a hospital spin-out unit or company incubator. In this phase, the 
main goals are to form, and maintain, the group membership, check the technical feasibility of a 
solution, and to understand the pathway to market by validating the clinical need. This latter point, 
we will explain, actually already requires a basic understanding of regulatory and clinical validation 
paths. At the end of the Form phase, the intrinsic value will typically amount to a proof-of-concept 
(PoC) solution and little more. 
 
Phase 2, we call the Build phase. At this point, a more defined team decides to work together for 
a period ranging from 18 months to 5 years. Clinical members may initially maintain other 
commitments, but they need to provide enough availability to help steer the development process. 
The goal of this phase is to build a basic implementation appropriate from a clinical and regulatory 
point-of-view. The outcomes of this phase are multimodal, but the intrinsic value at its end-point 
is a solid codebase which demonstrably solves a clinical need. 
 
Phase 3, Launch, is the phase which least matches current (consumer-oriented) software 
development practices. A medical product cannot directly enter the market without first passing 
certification and clinical validation steps. Therefore, processes such as medical device 
certification or a clinical study demonstrating efficacy must be carried out. In order to carry-out 
certification, or a study, typically the software version must be frozen. This does not mean, 
 however, that the team stops working. In our framework, there is still considerable technical work 
in this period. That said, the main goal of the phase is to complete the certification and validation 
steps. The end result of this phase is a product which can be deployed, in the majority of 
appropriate clinical settings, in the market. 
 
Definition of the 4 domains 
 
Clinical domain 
The clinical domain refers to the process of identifying real-world clinical needs and validating 
these needs throughout the life cycle of the project. Clinical needs are not just medical needs but 
extend to identifying different interaction requirements of different types of users (UI/UX research), 
and process-needs of all clinical partners, including patients and payers. We visualise, including 
supplementary advice, this domain in Figure 1. 
 
Regulatory domain 
Medical device regulation encompasses all laws and rules with regards to the development of a 
healthcare product falling under the definition of a medical device. AI in healthcare products are 
highly likely to fall under such regulations. We will explore for all three phases of a healthcare AI 
project, how to always be prepared for the regulatory requirements of the next phase and to 
deleverage critical risks early in the project. The particulars of regulatory processes differ 
enormously throughout the world, we will give only general advice which should apply across 
regions. A visualisation for the Regulatory domain appears in Figure 2. 
 
 
 
Data domain 
Since AI methods are inherently data-driven, the right kind of data is crucial to develop an AI-
based healthcare product. In the data domain sections, we will explore which kind of data needs 
to be leveraged in each phase. The data necessary for an early proof-of-concept to get traction 
can differ tremendously from the data which is necessary in later stages for certification and for 
clinical validation. We will highlight for each of the 3 phases, what data sources founders and 
developers should focus on. Figure 3 contains an overview. 
 
Algorithm domain  
 Another crucial domain is the choice of the AI methods applied for product development. With 
regards to the algorithms, attention must be paid: to the number of addressable patients in both 
the early training phases, but also in subsequent deployment; to questions of engineering around 
energy use, timeliness, and location of the data; to neglected populations in biased training 
samples; and, to the use of algorithms which will support any planned subsequent integration of 
other data streams. At every stage, we try to simplify this process outlining the long- and short-
term priorities and how the two should align. Figure 4 outlines the algorithm domain results. 
 
Form Phase 
The Form phase of a medical AI project can last 6-12 months and involves the earliest stages of 
proofing a concept around a digital solution to a perceived clinical need. 
 
Clinical domain 
The most important goals of the Form phase are to define a clinical need and to show that it is 
solvable in the form of a proof-of-concept. Clinicians are expert practitioners, and as such rely 
on their expertise to identify those clinical needs. Decades of experience in product design and 
development have shown, however, that while expert vision is useful for the identification of 
product-market fit, experts might fall too quickly in love with their own solutions and their own 
pet pain points [34,35]. This means, that the correct - objective - identification and validation of a 
clinical need is a high priority for the Form phase of development. The biggest risk for the Form 
phase is to focus on work that has no validated clinical need.  
 
A clinical need is not only defined as a clinical problem that needs solving. Since development is 
the goal, the solution for the clinical need at hand must either provide a proven clinical benefit - 
thus doctors will be led to use it despite potentially higher treatment costs - or it must reduce 
costs. If the solution neither reduces costs nor shows a proven clinical benefit, then the potential 
product is not financially viable. The team that needs to come together in the Form phase will 
thus need to be able to identify the clinical need, to validate it and build a first technical solution 
to address this need.  
 
Regulatory domain 
 Regulatory requirements are a significant hidden cost of development of medical AI solutions. 
Medical device regulators, such as the Federal Drug Administration (FDA) in the USA and 
European Medicines Agency (EMA) in the EU, have a mandate to protect the public from 
potentially dangerous medical interventions. This means that the choice to be regulated is 
rarely, in fact, a choice. Given this situation, entrepreneurs need to understand very early how 
their future product will be regulated. In the Form phase, it is unlikely that software developers 
will need to follow best practices for the development of a medical device. Most projects fall 
apart long before even a pilot study, so spending time and effort on regulatory compliant 
software-development processes at this early stage is inefficient. This is the time, however, for 
the founding team to familiarise themselves with the regulatory road ahead and to be aware of 
future requirements. Here, it is prudent to seek professional help as regulatory requirements are 
legally complex. This knowledge will build confidence with potential funders and will deleverage 
a large portion of Build (phase 2) risk ahead of time. 
 
Data domain 
New projects frequently lack access to fitting data or realise (too) late that access to promised 
data cannot be granted. Many clinicians are not aware of legal impediments to share data, for 
commercial use, so the decision to form a team should be based on clear evidence that data will 
be available and usable.  
 
When such initial data is successfully secured it is paramount to evaluate whether the data is 
supportive towards solving the identified clinical need. Here, clinical founders often overestimate 
the value of their initial dataset. While it is certainly admirable, and indeed necessary, to bring 
data to the table at the outset of a medical AI project, the iterative procedure of product 
development will often make the utility of the initial data set redundant.  
 
Any initial data set should be seen as an early research tool, from which to draw insights, which 
will contribute to the product development process. In the Form phase, it is enough to build 
models which can only predict outcomes based on this, typically, single-sourced - with multiple 
hidden biases - data. Practitioners should, however, begin to test the limits of their assumptions 
about this data. The urge to cherry-pick and to oversell the data utility, at this point, is only 
storing up larger problems for later. Be aware that a thorough validation of data hypotheses will 
be unavoidable in later stages. It is thus crucial to come up with a data plan outlining the 
usefulness of the currently used data and defining the need for future data sets.   
  
Algorithm domain 
Similar to the data domain, models developed in the Form phase will often be super-seeded in 
later stages. What is important in this early phase is to choose algorithms which are fit for 
purpose, not just with this smaller data set, but also with data on the intended deployment scale. 
Testing of multiple algorithms and the development of performance benchmarks are also very 
important. Choosing methods which over-perform on the initial data set, but which store up 
problems for subsequent expansion, along with performance metrics which are inappropriate for 
clinical applications are common errors at this point. 
 
A tempting self-deception is to fall into the habit of adopting bad scientific practices to produce 
initial results which in turn lead to very high chances of failure in later stages. We understand 
the need to show quickly initial results which will be the basis to attract further funding - be it 
public or private. However, sloppy development in this stage will lead to high failure rates in the 
Build phase, even if a clinical need exists and the team has the right data to solve it. 
 
Outlook 
Form is a crucial phase where a few vital key objectives need to be kept in mind. Foremost, the 
focus must lie on the validation of a clinical need and the development of a proof-of-concept to 
solve it. The clinical need must lead to reimbursement - either through proven clinical benefit or 
proven cost reduction. The formalisation of the data and algorithmic hypotheses, and associated 
benchmarks, is a demanding process for smaller teams. Thus, it is essential to focus on the key 
objectives. 
 
Build Phase 
Following the early incubation of the Form phase, comes Build, which can take as long as 2-5 
years depending on the type of product being developed. In this phase, a concerted effort is 
made to develop an AI-driven solution, while also demonstrating a clear clinical need.   
 
Clinical domain 
During the Build phase, it is highly important to continuously validate and fine-tune the clinical 
need, to make sure that the development process follows the right path. Due to the multi-modal 
 nature of product development, a typical product will morph multiple times during this phase. A 
strong risk, in this phase, is that one ends up with a technical solution which works well but no 
longer addresses the actual clinical need. Another potential risk is that the solution works on the 
available data but is actually non-performant on data from other sources (i.e. a highly biased 
model is developed). Thus, it is important to work with partner clinics, or practitioners, which are 
not directly under the control of the project initiator. This is partly to avoid complications of 
medical hierarchy, but also to expose the product development team to differences in clinical 
practices, hardware and opinions. Only this exposure will allow the team to fine-tune the 
solution to real-world needs. Especially in the Build phase, it is crucial to follow a predefined and 
continuously updated clinical validation plan. 
 
Regulatory domain 
The Build phase involves an earnest attempt to develop software which will form the bedrock of 
a future product. As such, this is the kick-off point for development of a solution which will 
withstand regulatory approval. There is the evident risk that incorrect assumptions are made 
about the required certification levels and the associated costs and timelines. In the worst case, 
this discovery is made so late in the Build phase that mistakes cannot be undone and the 
project or startup fails. It is also important to make sure that every single piece of technology is 
used in the correct manner for the certification process. 
 
There is a strong trade-off between instituting correct medical device (MD) certifiable software 
development processes early vs late in the product development cycle. The process overhead 
for developing an MD certified product is considerable, especially in a product which is not yet 
tightly designed to fit a product-market niche. However, introducing retrospective audits and 
new development processes late in the development cycle can be extremely financially costly 
and time-consuming. Potentially tipping the balance in favour of introducing MD certifiable 
guidelines early in the process, is the fact that this will also bed-down appropriate practices in 
the development team. Since these practices will need to be continued for the entire lifecycle of 
the product, it makes sense to begin as early as feasible. It is clear, however, that for some 
products, a later start might be the better option. The key is that decision-makers actively make 
an informed decision as to how to proceed and when development will switch to the scrutiny 
required for the certification process. 
 
Data domain 
 This is the stage at which external data sources must be aggregated with internal ones, allowing 
hypotheses about homogeneity and data quality to be assessed systematically for the first time. 
This, however, requires a strong focus on data processing and harmonization. It is important to 
make sure that the team has not only machine learning expertise but is also experienced in 
correct data processing. Since any work carried out in the Build phase is typically in very close 
partnership with clinics, or partners, it allows a relatively tight feedback loop on data which will 
not exist in later stages of development. Here, new datasets allow continuous assessment of 
the model performance. It is crucial to emulate in the Build phase the heterogeneity of the real 
world, e.g. in terms of different hardware or different clinical practices. 
   
Depending on the clinical need, it might be necessary to run a data collection study in the Build 
phase. For example, data from a new study might be necessary to reflect a change in current 
clinical practice, where retrospective data might not exactly reflect the use case anymore. It is 
also possible that in the Form phase the proof-of-concept was purely technical and data for the 
specific use case was not, at that point, available. It is crucial to understand that the data set, on 
which the medical AI product is built, can rarely be used for the subsequent validation of the 
product itself (see Launch phase and Discussion). At the end of the Build phase, the dataset 
must one-to-one reflect the real-world conditions to allow the development of models which will 
perform as well during medical certification and clinical validation as in-house.  
 
Algorithm domain 
Model development in the Build phase is tightly coupled to issues with data and clinical fit. With 
access to a larger data set, priority should be set on maintaining the predictive value, despite 
potential differences between the sources. It is not uncommon that the initial technology is 
unsuited to accommodating heterogeneous data. Thus, it happens frequently that the models 
need to be rebuilt from scratch in this phase, often with the assistance of more experienced 
engineers. 
 
Associated with predictive value, the single biggest issue in the Build phase is the mitigation of 
bias. The developed models must maintain predictive value on all real-world data which the 
future product will encounter and not just on a subpopulation. Patients from different regions can 
exhibit very different disease patterns, for example. In image generating fields, like 
radiology/pathology, different hardware (scanners/digitalization software) and different clinical 
practices (sequence settings/staining practices) can lead to tremendous differences in image 
 statistics. Thus, funders and founders should not be blinded by high predictive values on single-
source data. Models developed under such conditions can fail miserably when confronted with 
even slightly different datasets. 
 
From an engineering point of view, the finished product will be deployed somewhere and must 
fit into the clinical workflow. Choosing algorithms which both scale appropriately and are 
deployable in the context is vital. Algorithm designers should also bear in mind extensibility, a 
coherent product roadmap might incorporate plans for future data streams enabling potential 
extended applications. 
 
The Build phase is also the phase where the necessity of explainable AI (xAI) deserves to be 
considered. Applications, such as clinical decision support, might require explanations as the 
users (doctors) demand them [36] or are required to use them[37]. A more comprehensive 
product vision might even leverage xAI to provide different levels of explanation to different 
classes of users (e.g. doctors vs nurses vs patients). For the developers, it might be prudent to 
utilise xAI to identify potential hidden prediction biases. For example, it could be that a certain 
pathology is coupled to a certain hardware characteristic in the data. In that case, the model 
might learn to identify that hardware-tag instead of the pathology [38]. Most importantly, there 
are signs that xAI might be required by medical device regulatory authorities in the future [26].  
 
Outlook 
Build is the phase which most closely corresponds to the public perception of product 
development. Here, clinical validation should ideally switch from identifying the clinical need to 
fulfilling it. It is also the phase in which most companies stagnate. Reasons for that can be 
discoveries which indicate that initial assumptions about data were not accurate. Software 
solutions may be found to contain bugs or are more difficult to build than early results 
suggested. The largest effort, in this phase, must be applied to bringing all the components 
together. This applies on the software side, requiring not just the development of an AI tool but 
also a practical user interface (UI). But it applies equally to the validation side, users can never 
be forced to use your tool, they need to want to use it. Getting to this point requires many cycles 
of user interviews and testing. In Build, it is still possible that the true nature of the clinical need 
has been misinterpreted by the development team, or that the proposed technical solution is not 
capable of attaining the required level of performance. Ideally, however, this phase ends with a 
 product which is ready for medical device certification and efficacy studies and all major risks for 
the Launch phase have been kept as low as possible.  
 
Launch Phase 
The last phase, Launch, can take up to 3 years depending on the type of medical AI product. In 
this phase medical device certification is achieved and clinical validation is performed.  
 
Clinical domain 
The final clinical validation is proof that the product fulfils its promise in the clinical real-world 
setting. There are a few cases where retrospective data (also referred to as real-world 
evidence) might be used to ‘prove’ clinical products. There are clinical, regulatory and even 
statistical reasons [39] to argue that these cases will always prove to be a very small minority 
(see also the Discussion). In general, then, it will typically be necessary to run a clinical trial of 
any new AI-based medical product. The goal of this trial will be to prove not just safety but also 
clinical efficacy. This step is crucial. Without proven clinical efficacy - either for clinical benefit or 
for cost reduction - there is no real incentive for customers to buy the product. Thus, the 
successful completion of such a trial is usually the final step before widespread sales of the 
product in the medical-product marketplace can happen. 
 
It is crucial to understand that such a trial will almost always have to be a randomized controlled 
trial (RCT). Only RCTs can provide the necessary evidence level which is required to change 
clinical practice and to find their way into clinical standard-of-care guidelines. RCTs can also be 
designed to allow identification of effects on sub-populations, which is often necessary for AI-
based products. A major risk for the Launch phase is to underestimate the time and costs 
required for the planning and conduct of a RCT trial, which can amount to several years. 
 
Any evidence established by the trial will be subsequently examined under the lens of the trial 
design. A trial closer to real-world conditions will bring a higher value to the product (and will be 
necessary if the route to market requires changes to standards of care), but it runs a higher risk 
of failure due to uncontrolled conditions. This risk is mitigated by practices in the previous 
phases working with heterogeneous datasets and minimizing bias. To ensure an optimal trial 
outcome, it is highly advisable to allocate necessary funding and to work as early as possible 
 with a contract research organisation (CRO). Particular attention should be paid as to whether 
clinicians, in the trial, actually use the software in the manner expected by the designers. Once 
the product is approved and it appears on the market, further validation and changes will be 
extremely costly. 
 
Regulatory domain 
In many senses, the Launch phase is the regulatory phase. In it, the team will focus on the 
implementation of a fully compliant software development process and all steps necessary for 
medical certification will be taken. The major regulatory risk for this phase is that key 
assumptions about the certification process were wrong and the certification process is 
massively delayed. Importantly, this phase will also involve considerable efforts to consider the 
regulatory aspects of a product post-launch, when it is already in the market. Processes must 
be developed to handle surveillance of how the product behaves in real-world usage. If users 
report a bug, which may cause harm to life (i.e. an adverse event), product managers must 
already have contingency plans in place as to how this situation will be handled. Given the 
current state of medical device certification, negotiations must also be entered into with 
regulatory bodies as to how minor and bug-fixing software updates will be handled without 
requiring a re-run of clinical trials. A software solution which requires a complete clinical trial for 
every minor bug fix will not be worth much. By addressing these issues before they arise 
regulators will be more willing to put in place framework agreements laying out conditions for 
automatic certification of updates. 
 
Data domain 
The Launch phase is, in most cases, the final phase in which the development team can expect 
to see new forms of medical data. For certain cases, clinical trials can be constructed such that 
the internal team are, subsequently, allowed to train their models on the newly acquired data. 
Such a process will likely require backtesting, demonstrating that, had the new model been 
used throughout the trial then the algorithm behaviour would have been identical. What 
happens, however, in the case where backtesting indicates minor differences in treatments is 
still an open debate in regulatory circles. Notwithstanding, a major risk is that the data used in 
the previous stages were not heterogeneous enough and real-world data within the clinical 
validation is much noisier or so different that the predictive value does not hold. It is also 
paramount to ensure that the data collected in the clinical validation study actually represents 
the real-world setting. Here, it will be necessary to obtain proof for this claim. It should be kept in 
 mind that the acquisition of patient data directly from post-launch usage of the product is likely 
to be rare. It is true that a product which, through its usage, accretes additional knowledge 
about patients is an incredibly valuable product design. However, patient privacy practices 
throughout the world vary to such an enormous degree, that we find it unlikely that many 
products will successfully follow this path. Thus, data collection in this final pre-market phase 
must be planned and performed with the highest scrutiny.  
 
Algorithm domain 
The greatest risk in the Launch phase is that the final software solution will fail. It should be 
mentioned that at this stage, next to model failure, design failure can also be the cause. 
Extensive testing in Build, both on the model development and the UI/UX side, should help to 
keep the risk of such an outcome as low as possible. That said, AI models and software 
solutions around them fail at all stages of development. Typically, in Launch, this will occur due 
to some previously unrecognised regularities in in-house data (‘house effect’) which does not 
transfer to real-world data. Assuming such a catastrophic failure does not occur, algorithmic 
focus should be on how well the model transfers to out-of-house data. Often, despite all 
previous efforts, real-world data is still noisier and less homogenous than previously acquired 
data. The Launch phase is the last phase in which it is possible to easily detect lower 
performance on lower quality data and make final adjustments to the algorithms. In order to 
build a product which will reach market acceptance, it is important to be prepared for this 
challenge, to embrace it and to solve it. The team should be experienced enough by now.   
 
Outlook 
For a general non-medical digital start-up, the third phase is the one in which advice turns 
towards rapidly expanding the user base and optimising the product-market fit. In a medically 
regulated product, however, the third phase must precede rapid growth since the product needs 
to become certified and clinically validated. The processes for certification and clinical validation 
remain, to a certain degree, very much the last chance to get product-market fit aligned. 
Minimizing the risks in the previous phases of development and working with professional 
partners both for regulation and clinical validation will keep the risks for failure low in this final 
phase.   
 
 Post-market 
After completing Launch, the product development roadmap returns to that more typically seen in 
non-regulated markets. A certified medical AI product has been shown to be safe. If it has been 
through an RCT it may also demonstrate certain standards of clinical efficacy. In most cases, this 
means that a sales process can proceed and the delivery of the product massively scaled-up. 
Addition of new product features will usually follow a slightly condensed version of the Form-Build-
Launch cycle. For the product in the market, three topics remain of considerable ongoing concern: 
software updates, data practices and surveillance. 
 
Software, as it is developed today, is incredibly buggy. Even when following advanced software 
development best practices (e.g. B-Method [40]), software errors persist and must be corrected 
for. In physical medical devices, the electronic solutions follow decades of engineering-led best 
practices. In the event of a problem, the scale of the problem (risk) is analysed and regulators 
usually influence the decision as to whether to recall the product or merely fix it in future models. 
Software combines the ability to update the working system remotely, at almost zero cost, with a 
lower quality of initial engineering. Since software for medical purposes has seen relatively little 
development to-date no clear working regulatory practice has yet emerged. What is clear is that 
medical products are evaluated in terms of risk: What risks does this product pose to the 
patient? What if it goes wrong? What must happen if it goes wrong? This evaluation is carried 
out at the macro-level of the whole product, at the micro-level of the individual components, and 
at the intermediate-level of the interface which brings the components together. Development 
teams need to stay on top of shifting standards of best practice and, in all likelihood, should 
consider medical AI development to require similar levels of oversight as that historically 
required by aeronautical, spaceflight and automobile software development. 
 
A further, often overlooked process, in developing a medical AI solution is the question of 
shifting clinical standards. AI experts refer to this problem as stationarity of the data. For 
example, the diagnostic criteria, and how they are encoded in medical records, change over 
time. This is an expert-driven process which trickles down through medical practitioners. 
Development of a medical AI usually happens in a concentrated window in time, during which 
medical practices might be relatively stable, but the deployment of such a solution must then be 
used over a much longer time period. Detection, whether by automated means or by internal 
human-driven processes, of changes in medical practice must be planned-for and processes 
 established as to how to update the software in response. This is a huge challenge, as the 
whole process of Form, Build and Launch might be based on a single snapshot of clinical 
practice. A major shift in clinical practice can invalidate most of the work done during 
development.  
 
Surveillance is a concept which healthcare professionals and pharmaceutical manufacturers 
understand reasonably well. It is not something which software and AI developers will naturally 
consider without prompting. There must be feedback methods for reporting misapplications of 
the software in the wild. The spectrum of events which must be accounted for ranges from 
actual medical adverse events to users accidentally misunderstanding certain display elements. 
Most likely these methods must span the spectrum from paper-based reporting methods to in-
device automated monitoring. Furthermore, awareness must be paid to the fact that streaming 
of telemetry is usually frowned upon in medical circles; it is too easy to leak patients’ private 
medical data. We are not aware of good examples of medical AI device surveillance solutions 
which do not require ongoing access to patient medical records and extensive use of clinical 
review panels. No matter what the solution arrived at, it is the company producing the medical 
AI device which will be responsible for product surveillance and must pay for ongoing support in 
this domain or face a loss of medical certification. 
 
  
 Discussion 
 
Healthcare systems all over the world face the same challenges. There is an urgent need to 
deliver better quality healthcare and simultaneously lower costs to keep our healthcare systems 
sustainable. Artificial Intelligence has the potential to fulfil both of these requirements. While AI 
often hits the headlines with high performance in concept studies, certified and clinically validated 
products are still rare. To battle this translational gap, we present a framework addressing best 
practices for the development of AI healthcare products. 
  
The presented framework is an original and unique analysis of the development of AI healthcare 
products. It divides the development into three consecutive phases: Form, Build and Launch. 
Each phase is set to fulfil important requirements and deleverage the major risks of the 
subsequent phases. These three phases represent distinct stages as they appear in the course 
of the development of AI in healthcare products. Researchers, founders and other stakeholders 
should be able, with the aid of our framework, to easily identify the current phase and relative 
progress of a project. Within these three phases, the framework covers the 4 most important 
domains of such a project, namely the clinical, regulatory, algorithmic and data domains. Each 
domain must meet strict requirements in order to successfully complete the phase. If one of the 
areas is lagging behind, this will lead to the accumulation of - potentially fatal - risks for the project 
and jeopardise the product. 
 
We are not aware of other frameworks focusing on AI in healthcare product development to 
date. Our approach largely follows the “decision perspective” model introduced by Krishnan and 
Ulrich [30]. Its advantage is that it does not rely on the perspective of a single domain, but rather 
divides the development process in a series of decisions. Thus, for each phase, the right 
decisions can be made to achieve specific goals. This, of course, paves the way for future 
research work, which can focus on more specialised areas of AI in healthcare development 
such as marketing, organisations research and other topics. Importantly, the advantage of a 
decision perspective framework is the focus on what to do and not how to do it. Thus, 
frameworks focusing on how to best perform development are complementary to our framework 
as well as field-specific roadmaps aimed at the individual challenges to adopting AI [41]. The 
literature about this topic is too broad to be covered fully here. We will give a short overview of 
some frameworks in use. A key discovery, of the past 20 years, was the coining of the concept 
of an ‘effectual entrepreneur’ [42]. Such an entrepreneur works at the extreme end of low 
 inherent knowledge - unplannable processes. Over time, they develop an enterprise which 
increases inherent knowledge and beds down processes, which ultimately lead to a product. In 
start-up culture, such an entrepreneur is characterised by using product life cycle approaches 
such as Lean Startup or Agile (not to be confused with Toyota’s Lean manufacturing) [32,43]. 
Larger industries, attempting to learn from start-ups have adopted Design Thinking [44] - an 
essentially two-step process which begins by focusing on need before moving to Lean Startup-
style product development. From a funding point-of-view, the Business Model Canvas [45] has 
proved invaluable in identifying the product-market fit for new companies. Finally, the Three 
Lenses of Innovation -  a potential product must be desirable, feasible and viable - has proven 
useful to examine prospective market needs and product-market fit [46]. Our framework is both 
compatible with and extends these frameworks.  
 
Importantly, within the framework, we deliberately did not focus on funding schemes. The 
reason here is that current funding schemes often lead to a misalignment of interests. The 
reasons for this status-quo are complex. Current funding schemes for AI in healthcare products 
- often termed Digital Health - usually follow experiences from products outside of healthcare, 
derived in the modern digital era, where a sufficient return of investment (ROI) is expected 
within a few years. However, despite being digital software products, AI in healthcare products 
are much closer related to biotech products sharing the complex development and heavy 
regulatory requirements. Why then are funding schemes from biotech not adapted to the AI in 
healthcare sector? This can be attributed, in part, to the fact that the main exit for biotech 
companies is a combination of initial-public-offering (IPO) and merger and acquisition (M&A) 
[47], usually in partnership with large biotech or pharma companies. In general, outside of 
biotech, IPO activity has significantly decreased [48], meanwhile few large acquiring companies 
have emerged for medical AI. Thus, it is very hard for investors to ensure that a potentially very 
large investment sum will yield the required ROI. Relatively few investors are even aware of this 
challenge. Founders, whether unscrupulous or naive, attract investment by advertising their 
product niche as being equal to any other (AI) software. Or, by categorizing the product as a 
non-medical device, with stark consequences in terms of limiting their abilities or facing a 
regulatory backlash. Thus, AI in healthcare development is forced into following development 
paths of simpler products due to unreasonable expectations. This inevitably leads to founders 
cutting corners to pretend fast agile development. Evidently, such endeavours are bound to fail, 
when the hard requirements of medical device regulation and clinical validation cannot be met. 
In the words of venture capitalists, the main challenge for AI in healthcare startups is the so-
 called “valley of death”, where the startup already exists but does not generate revenue. This 
phase is usually equivalent to the Build + Launch phases in our framework. Thus, there is a 
need for an honest appraisal of the development roadmap for AI healthcare products. Here, our 
framework is an important contribution. Early-stage funding needs to be made aware of the true 
roadmap and timelines, and expectations need adjustment accordingly. As an example of 
increased public funding, a scheme specifically targeting the valley of death is currently set up 
by the European Union launching in 2021 [49]. As the sector matures, we hope that there will be 
an expansion of the acquisition activities by large pharma- and med-tech companies leading to 
a clearer pathway to product and company development. 
 
The above-identified crisis of the funding models for AI in healthcare products opens up the 
question as to how AI in healthcare products will be funded in the future. The current industry 
response which we have identified is to lobby for reduced regulations. The proposed rationale 
for this is that faster and less regulated technological innovation will ultimately deliver on the 
healthcare goals of broadening access while reducing costs. This cost argument has led to a 
willingness, on the part of regulators, to open up avenues for clearance of medical software 
solutions without the full burden associated with traditional pharmaceutical drug and medical 
device regulations. This opening of alternative regulatory routes is tempered by an awareness 
that medical AI can, and will, directly impact on patient health. In practice, however, the 
reduction of regulatory barriers appears to lead to a potential diversion of spending, from clinical 
validation and software engineering to paying experts on the navigation of such shortcuts - and 
a subsequent enormous payment for product-risk insurance when the product reaches the 
market. We do not see this as a sustainable path, indeed much of the current excitement 
around healthtech fails to appreciate that sales in this space are typically subject to subsequent 
regulatory approval. Additionally, the ethical implications of potentially endangering patients’ 
health in a trade-off for faster development are tremendous. Instead of reducing regulations, we 
suggest a more mature approach to clinical validation based on realistic approaches such as that 
contained in our framework. That said, there are alternatives. We see huge scope for the 
certification of AI ‘platforms’ or manufacturers where only the new components or the 
manufacturer need to be certified upon upgrades [50]. 
 
A related narrative is the increasing discussion of Real-World Data (RWD) as the real goldmine 
for AI in medicine. Currently, efforts are being made to allow Real-World Evidence (RWE) for 
the clinical validation of healthcare products [39,41,51]. What is the challenge of RWD for 
 clinical validation with regards to AI in healthcare products? Importantly, the term ‘AI’ only 
describes the method used in the product, not the model of medicine which lies behind it. Here, 
a significant observation is that many AI-solutions developed and marketed today can be 
considered - often unbeknownst to their creators - precision medicine approaches [52]. 
Precision medicine is a type of personalized medicine aiming to integrate all available data for 
each patient into an individual profile and tailoring diagnostics or therapy to this profile. AI is a 
great fit for precision medicine due to its inherent ability to utilize high-dimensional data to 
identify subpopulations and make individualized predictions [53]. Thus, RWD often allows the 
development of AI products - in the Form and Build phases - as, currently, only RWD has 
available data for sub-populations. In this sense, RWD can be seen as a driver of AI 
development. Data from classic randomized clinical trials (RCT), typically lack the granularity to 
distinguish differing populations and have - often - less value for AI in healthcare products. RWD 
is per definition retrospective and thus has - all widely known and accepted - drawbacks, e.g. 
bias, lack of controls, confounding and others [54]. Here, the main challenge is that availability is 
not a valid surrogate for the required level of evidence for safety and efficacy. One of the 
greatest hidden risks in a medical AI product developed on RWD is in algorithmically enforcing 
bias. And indeed, commercial products in healthcare have already been shown to contain 
considerable racial bias [55]. RCTs, in contrast, have been developed to minimize bias and 
confounding and provide the highest level of evidence. It is perfectly possible to perform an RCT 
to show efficacy and safety also for subpopulations and hence for any AI in healthcare product. 
The main difference is that a subpopulation RCT is very costly and time-consuming, as a 
sufficient number of patients per sub-group need to be enrolled. A push to use RWE instead of 
RCTs for the validation of AI in healthcare products is essentially a push to trade the level of 
evidence of safety and efficacy for lower costs, increased speed of development and higher risk 
for patients due to bias and confounding. It is fair to say that such a push would ethically and 
publicly never be acceptable if it was suggested for pharmaceutical products. Thus, it is hard to 
justify such a move for AI in healthcare products which often might have the same potential for 
patient risk. Consequently, our framework stresses the importance of an RCT as the required 
level of clinical validation for the overwhelming majority of AI in healthcare products in the 
Launch phase.  
 
In developing our framework we have largely envisaged medium- to high-risk medical AI 
products. This has streamlined our thought processes and allowed us to develop rules 
particularly of use to a medical audience. However, we don’t see any real differences in the 
 process for developing low-risk products. The only place where there is a question mark is in 
products which attempt to fall below all risk thresholds for medical regulation. At this point, we 
would question the wisdom of any strategy which looks at providing clinically-oriented benefits 
while attempting to market itself as a non-medical product. This continues to run the risk of 
falling foul of regulatory attention while also failing to attain the enhanced sales-values 
associated with medical products. In any case, a familiarity with our framework will allow key 
decision-makers to evaluate the potential costs and benefits of following a regulatory path. 
 
Conclusion 
 
We have developed a framework which outlines, what we consider to be, best practices in AI in 
healthcare development. Our goal is to pave the way for products which are both efficacious 
and safe for patients. Through direct participation in the development of a spectrum of medical 
AI products our experience, and that of our peers, is of enormous waste in the process. Current 
initiatives to improve the flow of AI in healthcare products aim at reducing costs and speeding 
up development through means which potentially increase risks for patients. Our framework 
outlines an alternative to this approach. We aim to improve the development situation of AI-
driven medical products by enhancing accountability, transparency and planning, hopefully 
increasing success rates for such products, without facing some of the safety and ethical trade-
offs mentioned above, to fulfil the promise of AI in healthcare: better care at lower costs. 
 
 
 
 
 
 
 
  
 References 
1.  (2020) Lifetime Risk of Developing or Dying From Cancer 
https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-
from-cancer.html. 
2.  (2018) Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. 
N. Engl. J. Med., 379 (25), 2429–2437. 
3. Griffiths, F., and Ooi, M. (2018) The fourth industrial revolution - Industry 4.0 and IoT 
[Trends in Future I M]. IEEE Instrum. Meas. Mag., 21 (6), 29–43. 
4. Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., Cui, C., 
Corrado, G., Thrun, S., and Dean, J. (2019) A guide to deep learning in healthcare. Nat. 
Med., 25 (1), 24–29. 
5. Leshno, M., Lin, V.Ya., Pinkus, A., and Schocken, S. (1993) Multilayer feedforward 
networks with a nonpolynomial activation function can approximate any function. Neural 
Netw., 6 (6), 861–867. 
6. Zhang, Z., Zhao, Y., Canes, A., Steinberg, D., Lyashevska, O., and AME Big-Data 
Clinical Trial Collaborative Group, W. on B.O. (2019) Predictive analytics with gradient 
boosting in clinical medicine. Ann. Transl. Med., 7 (7). 
7. Breiman, L., Friedman, J., Stone, C.J., and Olshen, R.A. (1984) Classification and 
Regression Trees, Chapman and Hall/CRC, Boca Raton. 
8. Podgorelec, V., Kokol, P., Stiglic, B., and Rozman, I. (2002) Decision Trees: An 
Overview and Their Use in Medicine. J. Med. Syst., 26 (5), 445–463. 
9. McCullagh, and Nelder Generalized Linear Models. CRC Press. 
10. Cortes, C., and Vapnik, V. (1995) Support-vector networks. Mach. Learn., 20 (3), 273–
297. 
11. Mammone, A., Turchi, M., and Cristianini, N. (2009) Support vector machines. WIREs 
Comput. Stat., 1 (3), 283–289. 
12. Rasmussen, C.E., and Williams, C.K.I. (2006) Gaussian processes for machine learning, 
MIT Press, Cambridge, Mass. 
13. Seeger, M. (2004) Gaussian processes for machine learning. Int. J. Neural Syst., 14 
(02), 69–106. 
14. Patel, P., and Thakkar, A. (2020) The upsurge of deep learning for computer vision 
applications. Int. J. Electr. Comput. Eng. IJECE, 10 (1), 538–548. 
15. Peters, M.E., Neumann, M., Iyyer, M., Gardner, M., Clark, C., Lee, K., and Zettlemoyer, 
L. (2018) Deep contextualized word representations. ArXiv180205365 Cs. 
16. Saha, J., Chowdhury, C., and Biswas, S. (2020) Review of Machine Learning and Deep 
Learning Based Recommender Systems for Health Informatics, in Deep Learning 
Techniques for Biomedical and Health Informatics (eds.Dash, S., Acharya, B.R., Mittal, M., 
Abraham, A., and Kelemen, A.), Springer International Publishing, Cham, pp. 101–126. 
17. Rendle, S. (2010) Factorization Machines. Proc. 2010 IEEE Int. Conf. Data Min., 995–
1000. 
18. Ying, R., He, R., Chen, K., Eksombatchai, P., Hamilton, W.L., and Leskovec, J. (2018) 
Graph Convolutional Neural Networks for Web-Scale Recommender Systems. Proc. 24th 
ACM SIGKDD Int. Conf. Knowl. Discov. Data Min., 974–983. 
19. Panesar, A. (2019) Future of Healthcare, in Machine Learning and AI for Healthcare
 : Big Data for Improved Health Outcomes (eds.Panesar, A.), Apress, Berkeley, CA, pp. 
255–304. 
20. Savino, J.A., and Latifi, R. (2019) The Hospital of the Future: Evidence-Based, Data-
Driven, in The Modern Hospital: Patients Centered, Disease Based, Research Oriented, 
Technology Driven (eds.Latifi, R.), Springer International Publishing, Cham, pp. 375–387. 
21. Livne, M. (2019) Precision Medicine in Stroke powered by AI - promises and challenges, 
 in XPOMET©: 360° Next Generation Healthcare, MWV Medizinisch Wissenschaftliche 
Verlagsgesellschaft. 
22. Basch, E., Deal, A.M., Dueck, A.C., Scher, H.I., Kris, M.G., Hudis, C., and Schrag, D. 
(2017) Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for 
Symptom Monitoring During Routine Cancer Treatment. JAMA, 318 (2), 197–198. 
23. Hosny, A., Parmar, C., Quackenbush, J., Schwartz, L.H., and Aerts, H.J.W.L. (2018) 
Artificial intelligence in radiology. Nat. Rev. Cancer, 18 (8), 500. 
24. Larios Delgado, N., Usuyama, N., Hall, A.K., Hazen, R.J., Ma, M., Sahu, S., and Lundin, 
J. (2019) Fast and accurate medication identification. Npj Digit. Med., 2 (1), 1–9. 
25. Davenport, T., and Kalakota, R. (2019) The potential for artificial intelligence in 
healthcare. Future Heal. J, 6 (2), 94–98. 
26. Reddy, S., Fox, J., and Purohit, M.P. (2019) Artificial intelligence-enabled healthcare 
delivery. J. R. Soc. Med., 112 (1), 22–28. 
27. Racine, E., Boehlen, W., and Sample, M. (2019) Healthcare uses of artificial intelligence: 
Challenges and opportunities for growth. Healthc. Manage. Forum, 32 (5), 272–275. 
28. Ben-Israel, D., Jacobs, W.B., Casha, S., Lang, S., Ryu, W.H.A., de Lotbiniere-Bassett, 
M., and Cadotte, D.W. (2020) The impact of machine learning on patient care: A systematic 
review. Artif. Intell. Med., 103, 101785. 
29. Kim, D.W., Jang, H.Y., Kim, K.W., Shin, Y., and Park, S.H. (2019) Design 
Characteristics of Studies Reporting the Performance of Artificial Intelligence Algorithms for 
Diagnostic Analysis of Medical Images: Results from Recently Published Papers. Korean J. 
Radiol., 20 (3), 405–410. 
30. Krishnan, V., and Ulrich, K.T. (2001) Product Development Decisions: A Review of the 
Literature. Manag. Sci., 47 (1), 1–21. 
31. Masters, B., and Thiel, P. (2015) Zero to One: Notes on Start Ups, or How to Build the 
Future, Virgin Books, London. 
32. Ries, E. (2011) The Lean Startup: How Today’s Entrepreneurs Use Continuous 
Innovation to Create Radically Successful Businesses, Currency, New York. 
33. Gordon, W.J., Landman, A., Zhang, H., and Bates, D.W. (2020) Beyond validation: 
getting health apps into clinical practice. Npj Digit. Med., 3 (1), 1–6. 
34. Englich, B., Mussweiler, T., and Strack, F. (2016) Playing Dice With Criminal Sentences: 
The Influence of Irrelevant Anchors on Experts’ Judicial Decision Making: Pers. Soc. 
Psychol. Bull. 
35. Bergman, O., Ellingsen, T., Johannesson, M., and Svensson, C. (2010) Anchoring and 
cognitive ability. Econ. Lett., 107 (1), 66–68. 
36. Shortliffe, E.H., and Sepúlveda, M.J. (2018) Clinical Decision Support in the Era of 
Artificial Intelligence. JAMA, 320 (21), 2199–2200. 
37. Hacker, P., Krestel, R., Grundmann, S., and Naumann, F. (2020) Explainable AI under 
Contract and Tort Law: Legal Incentives and Technical Challenges. 
38. Zech, J.R., Badgeley, M.A., Liu, M., Costa, A.B., Titano, J.J., and Oermann, E.K. (2018) 
Variable generalization performance of a deep learning model to detect pneumonia in chest 
radiographs: A cross-sectional study. PLOS Med., 15 (11), e1002683. 
39. Wilkinson, J., Brison, D.R., Duffy, J.M.N., Farquhar, C.M., Lensen, S., Mastenbroek, S., 
van Wely, M., and Vail, A. (2019) Don’t abandon RCTs in IVF. We don’t even understand 
them. Hum. Reprod., 34 (11), 2093–2098. 
40. Schneider, S. (2001) The B-Method, Red Globe Press, Basingstoke, Hampshire. 
41. Allen, B., Seltzer, S.E., Langlotz, C.P., Dreyer, K.P., Summers, R.M., Petrick, N., 
Marinac-Dabic, D., Cruz, M., Alkasab, T.K., Hanisch, R.J., Nilsen, W.J., Burleson, J., 
Lyman, K., and Kandarpa, K. (2019) A Road Map for Translational Research on Artificial 
Intelligence in Medical Imaging: From the 2018 National Institutes of Health/RSNA/ACR/The 
Academy Workshop. J. Am. Coll. Radiol., 16 (9), 1179–1189. 
 42. Sarasvathy, S.D. (2001) Causation and Effectuation: Toward a Theoretical Shift from 
Economic Inevitability to Entrpreneurial Contingency. Acad. Manage. Rev., 22. 
43. Manjunath, K.N., Jagadeesh, J., and Yogeesh, M. (2013) Achieving quality product in a 
long term software product development in healthcare application using Lean and Agile 
principles: Software engineering and software development. 2013 Int. Mutli-Conf. Autom. 
Comput. Commun. Control Compress. Sens. IMac4s, 26–34. 
44. Roberts, J.P., Fisher, T.R., Trowbridge, M.J., and Bent, C. (2016) A design thinking 
framework for healthcare management and innovation. Healthcare, 4 (1), 11–14. 
45. León, M.C., Nieto-Hipólito, J.I., Garibaldi-Beltrán, J., Amaya-Parra, G., Luque-Morales, 
P., Magaña-Espinoza, P., and Aguilar-Velazco, J. (2016) Designing a Model of a Digital 
Ecosystem for Healthcare and Wellness Using the Business Model Canvas. J. Med. Syst., 
40 (6), 144. 
46.  (2020) How to Prototype a New Business https://www.ideou.com/blogs/inspiration/how-
to-prototype-a-new-business. IDEO U. 
47. Silicon Valley Bank (2019) 2019 annual healthcare report 
https://www.svb.com/globalassets/library/managedassets/pdfs/healthcare-report-2019-
annual.pdf. 
48. Gao, X., Ritter, J.R., and Zhu, Z. (2013) Where Have All the IPOs Gone? J. Financ. 
Quant. Anal., 48 (6), 1663–1692. 
49.  (2019) EU Plans $3.9 Billion Fund for Startups in ‘Valley of Death’ 
https://www.bloomberg.com/news/articles/2019-11-23/eu-plans-3-9-billion-fund-for-startups-
in-valley-of-death. Bloomberg.com. 
50. FDA Pre-Cert, C. for D. and R. (2019) Digital Health Software Precertification (Pre-Cert) 
Program http://www.fda.gov/medical-devices/digital-health/digital-health-software-
precertification-pre-cert-program. FDA. 
51. Dreyer, N.A. (2018) Advancing a Framework for Regulatory Use of Real-World 
Evidence: When Real Is Reliable. Ther. Innov. Regul. Sci., 52 (3), 362–368. 
52. Kosorok, M.R., and Laber, E.B. (2019) Precision Medicine. 26. 
53. Miller, D.D., and Brown, E.W. (2018) Artificial Intelligence in Medical Practice: The 
Question to the Answer? Am. J. Med., 131 (2), 129–133. 
54. Franklin, J.M., and Schneeweiss, S. (2017) When and How Can Real World Data 
Analyses Substitute for Randomized Controlled Trials? Clin. Pharmacol. Ther., 102 (6), 
924–933. 
55. Obermeyer, Z., Powers, B., Vogeli, C., and Mullainathan, S. (2019) Dissecting racial bias 
in an algorithm used to manage the health of populations. Science, 366 (6464), 447–453. 
 
 
 
 
Disclosures 
David Higgins works as a freelance advisor to AI in healthcare companies. Vince Madai is also 
CSO of ai4medicine, a company developing AI in healthcare products and advising on AI in 
healthcare product development.  
 
Acknowledgements 
We would like to acknowledge Michelle Livne, Nicholas Borsotto, Tim Higgins and Dorothée 
Doepfer for valuable ideas and proofreading.  
 




